OBJECTIVE: The relationship between serum viremia and the development of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-related cirrhosis remains unclear. We aimed at calculating odds ratios (OR) for the presence of HCC over a range of HBV DNA levels in these patients. METHODS: Patients were identified retrospectively and 155 pairs of matched, treatment-naive HBV-related cirrhotic patients with and without HCC were recruited. Their serum HBV DNA levels were measured at HCC diagnosis, or at the equivalent age in non-HCC patients, and correlations between the presence of HCC and different DNA levels were calculated using conditional logistic regression. RESULTS: The median HBV DNA level was significantly higher in HCC patients than in non-HCC patients (5.15 vs 4.83 log(10) copies/mL, P = 0.024). The overall OR for HCC in patients with HBV DNA > or = 3 log(10) copies/mL was 2.13, compared with patients with levels <3 log(10) copies/mL. Compared with patients with <3 log(10) copies/mL, the OR for HCC were 2.39 and 2.61 for patients with 4 to <5 and 5 to <6 log(10) copies/mL, respectively, while the OR for DNA levels of > or = 6 log(10) copies/mL were not significantly different. CONCLUSION: In HBV-related cirrhosis, a detectable serum HBV DNA was associated with the presence of HCC, but the likelihood of having HCC did not successively increase with increasing serum HBV DNA levels: patients with serum HBV DNA levels between 4 and <6 log(10) copies/mL were most likely to present with HCC.
OBJECTIVE: The relationship between serum viremia and the development of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-related cirrhosis remains unclear. We aimed at calculating odds ratios (OR) for the presence of HCC over a range of HBV DNA levels in these patients. METHODS:Patients were identified retrospectively and 155 pairs of matched, treatment-naive HBV-related cirrhotic patients with and without HCC were recruited. Their serum HBV DNA levels were measured at HCC diagnosis, or at the equivalent age in non-HCC patients, and correlations between the presence of HCC and different DNA levels were calculated using conditional logistic regression. RESULTS: The median HBV DNA level was significantly higher in HCC patients than in non-HCC patients (5.15 vs 4.83 log(10) copies/mL, P = 0.024). The overall OR for HCC in patients with HBV DNA > or = 3 log(10) copies/mL was 2.13, compared with patients with levels <3 log(10) copies/mL. Compared with patients with <3 log(10) copies/mL, the OR for HCC were 2.39 and 2.61 for patients with 4 to <5 and 5 to <6 log(10) copies/mL, respectively, while the OR for DNA levels of > or = 6 log(10) copies/mL were not significantly different. CONCLUSION: In HBV-related cirrhosis, a detectable serum HBV DNA was associated with the presence of HCC, but the likelihood of having HCC did not successively increase with increasing serum HBV DNA levels: patients with serum HBV DNA levels between 4 and <6 log(10) copies/mL were most likely to present with HCC.